 Traumatic brain injury (TBI) remains a major problem in the United States, with more than a million injuries occurring each year. TBI is responsible not only for deaths but also for a tremendous burden of long-term disability.  For patients who have sustained a TBI, anticonvulsants are used to decrease the incidence of posttraumatic seizures; these seizures are classified as early (occurring within 7 days of injury) or late (occurring after 7 days).  Untreated the incidence of early posttraumatic seizures has been estimated to be between 4% and 25%.  Recently the use of levetiracetam (LEV) for seizure prophylaxis has increased, owing in part to the ease of dosing and lack of need for drug level monitoring.  Phenytoin (PHE) has been associated with several rare serious adverse effects including cutaneous hypersensitivity and CYP450 induction, leading to drug interactions not seen with LEV.  Although convenient, very little evidence exists to support the efficacy of LEV for early PTS. In addition, the cost of LEV is several fold that of PHE.
OBJECTIVE
 To compare the efficacy of phenytoin to levetiracetam for the prevention of early posttraumatic seizures o 406 patients received levetiracetam 1,000mg IV every 12 hours, given over 15 minutes o 407 received a phenytoin 20mg/kg IV loading dose (maximum of 2,000mg) given at 50mg/minute. These patients were then started on a maintenance dose of 5mg/kg/day (rounded to the nearest 100mg) IV administered every 8 hours, given over 15 minutes. Phenytoin serum levels were checked daily after enrollment and dosing was adjusted by an institutional pharmacist as needed to maintain therapeutic levels.  340 were admitted to LAC-USC (329-levetiracetam and 11-phenytoin)  473 were admitted to R. Adams Cowley Shock Trauma Center (77-levetiracetam and 396-phenytoin)  Once tolerating a diet, patients were switched to oral administration  All drugs given were documented, including date and time of administration and reason for use.  All patients were maintained on study medications for 7 days; if no clinical seizures were detected at this time, the study medication was discontinued  In the event of a seizure, the clinical neurology team was consulted and antiseizure medication was individualized  Power 80% with an alpha level of 0.05 to detect a 0.22 difference between 8% and 14% (the early seizure rate with PHE and LEV, respectively, in previous trials). This was calculated to be sufficient for at least 392 patients in each group.  Data handling method was intent-to-treat
METHODS

RESULTS
 Primary outcome measure: o There were no significant differences in seizure rates (LEV 1.5% vs. PHE 1.5%, p=0. o Patients who received levetiracetam had increased hospital lengths of stay (LOS) (LEV 11.8 vs. PHE 7.5, p<0.001)  When adverse drug reactions were analyzed individually, patients who received LEV had a significantly lower incidence of leukocytosis (LEV 1.2% vs. PHE 9.6%, p<0.001).  More patients who were started on PHE had their treatment discontinued owing to an adverse effect (LEV 0% vs. PHE 2.9%, p<0.001); however, in each of these cases prophylaxis was transitioned to LEV with no adverse outcomes or seizures noted after the medication change.
STRENGTHS
 Parallel study design  Medications were dosed appropriately and in a comparable manner for a sufficient duration.  Due to the nature of the study adherence and dropout were not issues.  None of the authors declared any conflicts of interest.
LIMITATIONS
 EEG monitoring to detect subclinical seizures was not performed at either of the two study centers.  Only blunt trauma patients were enrolled.  Patients and investigators were not blinded to the treatment regimens.  Patients were not randomized to an anticonvulsant treatment regimen.  Differences between institutions in discharge planning and ability to place these patients into rehab settings affected hospital length of stay time.  Alcohol use was not examined.
CONCLUSIONS
 There is no apparent efficacy advantage for use of levetiracetam over phenytoin in early posttraumatic seizure prophylaxis.  There are no statistically significant differences in the overall complication, adverse reaction, or mortality rate between the two agents.  In practice, the cost and need for serum monitoring should be considered in guiding the choice of prophylactic agent.  Currently, levetiracetam is several fold more expensive than phenytoin, but these agents will become increasingly comparable as the price per course of levetiracetam declines over time.  Future Research:
o Additional multicenter, double-blind, randomized trials are needed to confirm the findings of this investigation. Logan Sanders, PharmD Candidate
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